Related Experiment Videos
The platelet aggregation in children with epilepsy receiving valproic acid
S Tanindi1, R Akin, V Koseoglu
1Department of Pediatrics, Gulhane Military Medical Academy, Ankara, Turkey.
Thrombosis Research
|February 15, 1996
Summary
Valproic acid, used for epilepsy, does not significantly affect platelet aggregation in children. This study found the medication reliable for epilepsy management without causing platelet dysfunction.
Area of Science:
- Pediatric Neurology
- Hematology
- Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Valproic acid is a widely used antiepileptic drug.
- Potential effects of valproic acid on platelet function require evaluation.
Purpose of the Study:
- To assess changes in whole blood aggregation in pediatric epilepsy patients on valproic acid.
- To compare platelet aggregation between children with epilepsy and healthy adults.
- To determine if serum valproic acid levels correlate with platelet aggregation.
Main Methods:
- Whole blood platelet aggregation was studied using impedance aggregometry.
- Included 25 children with epilepsy and 15 healthy adult volunteers.
- Measured platelet counts, bleeding times, clotting times, and aggregation values.
Main Results:
- Platelet counts, bleeding, and clotting times were normal in patients.
- No significant differences in aggregation time or maximum aggregation, except with 2 μg/ml collagen.
- Serum valproic acid levels showed no correlation with aggregation, except with 20 μM ADP.
Conclusions:
- Valproic acid, within therapeutic limits, does not cause thrombocytopenia or platelet dysfunction in children.
- The study supports the reliability of valproic acid for epilepsy management.
- Platelet function remains largely unaffected by valproic acid treatment in pediatric epilepsy.